Deciphera Pharmaceuticals, LLC - Product Pipeline Review - Q4 2010

GlobalData, November 2010, Pages: 31

Deciphera Pharmaceuticals, LLC – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Deciphera Pharmaceuticals, LLC - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Deciphera Pharmaceuticals, LLC - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Deciphera Pharmaceuticals, LLC human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Deciphera Pharmaceuticals, LLC with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Deciphera Pharmaceuticals, LLC’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Deciphera Pharmaceuticals, LLC’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Deciphera Pharmaceuticals, LLC in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Deciphera Pharmaceuticals, LLC’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Deciphera Pharmaceuticals, LLC.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Deciphera Pharmaceuticals, LLC and identify potential opportunities in those areas.

List of Tables
List of Figures
Deciphera Pharmaceuticals, LLC Snapshot
Deciphera Pharmaceuticals, LLC Overview
Key Information
Key Facts
Deciphera Pharmaceuticals, LLC – Research and Development Overview
Key Therapeutic Areas
Deciphera Pharmaceuticals, LLC – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Deciphera Pharmaceuticals, LLC – Pipeline Products Glance
Deciphera Pharmaceuticals, LLC Clinical Stage Pipeline Products
Phase I Products/Combination Treatment Modalities
Deciphera Pharmaceuticals, LLC–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Deciphera Pharmaceuticals, LLC – Drug Profiles
DCC-2036
Product Description
Mechanism of Action
R&D Progress
DCC-2157
Product Description
Mechanism of Action
R&D Progress
DP-2514
Product Description
Mechanism of Action
R&D Progress
DP-3346
Product Description
Mechanism of Action
R&D Progress
DP-3407
Product Description
Mechanism of Action
R&D Progress
DP-3429
Product Description
Mechanism of Action
R&D Progress
DP-3590
Product Description
Mechanism of Action
R&D Progress
Deciphera Pharmaceuticals, LLC – Pipeline Analysis
Deciphera Pharmaceuticals, LLC – Pipeline Products by Therapeutic Class
Deciphera Pharmaceuticals, LLC Pipeline Products By Target
Deciphera Pharmaceuticals, LLC – Pipeline Products by Route of Administration
Deciphera Pharmaceuticals, LLC – Locations And Subsidiaries
Head Office
Recent Developments
Mar 25, 2009: Deciphera Pharmaceuticals Announces Initation Of DCC-2036 Phase I Clinical Trial In Refractory CML and ALL
Mar 25, 2009: Deciphera Pharmaceuticals Announces Initation Of DCC-2036 Phase I Clinical Trial In Refractory CML and ALL
Financial Deals Landscape
Deciphera Pharmaceuticals, LLC, Deals Summary, 2004 to 2010
Deciphera Pharmaceuticals, LLC Detailed Deal Summary
Eli Lilly Enters Into Agreement With Deciphera Pharmaceuticals
deCODE Extends Research Agreement With Deciphera Pharmaceuticals
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Customers who bought this item also bought

• Biodefense Industry - Market to Benefit from Federal Funding such as the BIO EDEP Fund to Support Security Plans
• eLEARNING - Global Strategic Business Report
• Charter Schools - Global Outlook
• Aerospace and Defense Industry - Global Strategic Business Report
• Education Services - Global Strategic Business Report
• Commercial And Military Flight Simulation - Global Strategic Business Report
• Sports and Fitness Nutrition - Global Strategic Business Report
• The Future of the Biodefense Industry: Regulation, Funding Opportunities & Company Profiles
• International Military and Government Helicopter Survey
• Private Tutoring - Global Strategic Business Report